[Euthanasia--limits of therapy in oncology. From the viewpoint of the medical psychologist].

Wien Klin Wochenschr

Institut für Medizinische Psychologie, Universität Wien.

Published: October 1990

Progress in organic-technical medicine has been considerable in the field of oncology. Since cancer patients are confronted with enormous psychological problems both by their disease and its treatment, improvement in the psychological care of these patients is an absolute necessity. At present, help in coping with cancer is seldom provided. Psychological care of cancer patients would be of great importance for improving the quality of life, which always has to be assessed according to the patient's subjective point of view. The aim should be to keep patients not only alive but also all terms with life. In the terminal stages pain relief and consolidation of the sick are prerequisites for dying in dignity.

Download full-text PDF

Source

Publication Analysis

Top Keywords

cancer patients
8
psychological care
8
[euthanasia--limits therapy
4
therapy oncology
4
oncology viewpoint
4
viewpoint medical
4
medical psychologist]
4
psychologist] progress
4
progress organic-technical
4
organic-technical medicine
4

Similar Publications

Acute leukemia (AL) affects patients' well-being and inflicts substantial symptom burden. We evaluated palliative care needs and symptom burden in adult patients with AL from diagnosis through fourth week of induction chemotherapy. Newly diagnosed adult patients with AL scheduled for curative-intent treatments, prospectively completed Functional Assessment of Cancer Therapy-Leukemia questionnaire at diagnosis and postinduction therapy.

View Article and Find Full Text PDF

Importance: Three similar phase 3 randomized clinical trials have investigated PD-1/PD-L1 (programmed cell death 1 protein/programmed cell death 1 ligand 1) inhibitors in combination with platinum-based chemotherapy vs chemotherapy alone as first-line treatment for advanced urothelial carcinoma (IMvigor130, atezolizumab; KEYNOTE-361, pembrolizumab; and CheckMate901, nivolumab). Only CheckMate901 reported overall survival (OS) benefit for the combination. The reason for these inconsistent results is unclear.

View Article and Find Full Text PDF

Immunomodulatory drug (IMiD) resistance is a key clinical challenge in myeloma treatment. Previous data suggests almost one third of myeloma patients acquire mutations in the key IMiD effector cereblon by the time they are pomalidomide refractory. Some events, including stop codons/frameshift mutations and copy loss, having clearly explicable effects on cereblon function.

View Article and Find Full Text PDF

Stemness-associated cell states are linked to chemotherapy resistance in AML. We uncovered a direct mechanistic link between expression of the stem cell transcription factor GATA2 and drug resistance. The GATA-binding protein 2 (GATA2) plays a central role in blood stem cell generation and maintenance.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!